 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12...6789101112131415161718» |
- || tolcapone (CRX-1008) / Corino Therap, SOM Biotech
Trial completion: A Study Assessing the Safety and Pharmacokinetic Profile of Modified Release Formulations of Tolcapone (clinicaltrials.gov) - Jan 31, 2019
P1, N=12, Completed, Sponsor: Corino Therapeutics, Inc.
Active, not recruiting --> Completed
- | prexasertib (LY2606368) / Eli Lilly, Pfizer, SOM Biotech, Ewha Womans University
P2 data, Journal, BRCA Biomarker: Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. (Pubmed Central) - Jan 29, 2019
P2
Prexasertib showed clinical activity and was tolerable in patients with BRCA wild-type high-grade serous ovarian carcinoma. This drug warrants further development in this setting, especially for patients with platinum-resistant or platinum-refractory disease.
- | prexasertib (ACR-368) / Acrivon Therap
Trial completion date: Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Jan 28, 2019
P1, N=16, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
This drug warrants further development in this setting, especially for patients with platinum-resistant or platinum-refractory disease. Trial completion date: May 2022 --> May 2021
- || prexasertib (ACR-368) / Acrivon Therap
Enrollment open, Combination therapy: Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial (clinicaltrials.gov) - Jan 25, 2019
P1, N=28, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: May 2022 --> May 2021 Not yet recruiting --> Recruiting
- | prexasertib (ACR-368) / Acrivon Therap, lodapolimab (LY3300054) / Eli Lilly
New P1 trial, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 19, 2019
P1, N=28, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- || Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Enrollment open: A Safety and PK Study of IV Eravacycline (clinicaltrials.gov) - Jan 4, 2019
P1, N=20, Recruiting, Sponsor: Tetraphase Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || prexasertib (ACR-368) / Acrivon Therap, ralimetinib (LY 2228820) / Eli Lilly
Enrollment change, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov) - Dec 14, 2018
P1, N=9, Completed, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting N=70 --> 9
- ||||||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Trial completion: Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections (clinicaltrials.gov) - Dec 11, 2018
P3, N=908, Completed, Sponsor: Tetraphase Pharmaceuticals, Inc.
N=70 --> 9 Active, not recruiting --> Completed
- | tolcapone (CRX-1008) / Corino Therap, SOM Biotech
Enrollment status: Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) (clinicaltrials.gov) - Nov 28, 2018
P1, N=10, Recruiting, Sponsor: Boston University
Active, not recruiting --> Completed Enrolling by invitation --> Recruiting
- | prexasertib (ACR-368) / Acrivon Therap
Trial completion date: A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer (clinicaltrials.gov) - Nov 21, 2018
P2, N=131, Active, not recruiting, Sponsor: Eli Lilly and Company
Enrolling by invitation --> Recruiting Trial completion date: Nov 2018 --> Feb 2019
- | prexasertib (ACR-368) / Acrivon Therap
New P1 trial, Combination therapy: Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial (clinicaltrials.gov) - Nov 8, 2018
P1, N=28, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- | Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
New P1 trial: A Safety and PK Study of IV Eravacycline (clinicaltrials.gov) - Oct 3, 2018
P1, N=20, Not yet recruiting, Sponsor: Tetraphase Pharmaceuticals, Inc.
- | tolcapone (CRX-1008) / Corino Therap, SOM Biotech
Enrollment open: Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) (clinicaltrials.gov) - Sep 14, 2018
P1, N=10, Enrolling by invitation, Sponsor: Boston University
Trial completion date: Nov 2018 --> Feb 2019 Not yet recruiting --> Enrolling by invitation
- | prexasertib (ACR-368) / Acrivon Therap
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer (clinicaltrials.gov) - Sep 13, 2018
P1b, N=70, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Enrolling by invitation Trial completion date: Oct 2018 --> Jan 2019 | Trial primary completion date: Oct 2018 --> Jan 2019
- | prexasertib (ACR-368) / Acrivon Therap
Enrollment closed: A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer (clinicaltrials.gov) - Sep 6, 2018
P2, N=131, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Oct 2018 --> Jan 2019 | Trial primary completion date: Oct 2018 --> Jan 2019 Recruiting --> Active, not recruiting
- | tolcapone (CRX-1008) / Corino Therap, SOM Biotech
New P1 trial: A Study Assessing the Safety and Pharmacokinetic Profile of Modified Release Formulations of Tolcapone (clinicaltrials.gov) - Aug 15, 2018
P1, N=12, Active, not recruiting, Sponsor: Corino Therapeutics, Inc.
- | prexasertib (ACR-368) / Acrivon Therap
Enrollment closed, Enrollment change: Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 13, 2018
P1, N=16, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=40 --> 16
- | prexasertib (ACR-368) / Acrivon Therap
Trial completion date: Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (clinicaltrials.gov) - Aug 9, 2018
P1, N=65, Recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting | N=40 --> 16 Trial completion date: Jul 2020 --> Jul 2019
- | bevantolol (SOM3355) / SOM Biotech
Enrollment open: Efficacy and Safety of SOM3355 in Huntington's Disease Chorea (clinicaltrials.gov) - Jul 27, 2018
P2a, N=30, Recruiting, Sponsor: SOM Biotech SL
Trial completion date: Jul 2020 --> Jul 2019 Not yet recruiting --> Recruiting
- | tolcapone (CRX-1008) / Corino Therap, SOM Biotech
New P1 trial: Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) (clinicaltrials.gov) - Jul 19, 2018
P1, N=10, Not yet recruiting, Sponsor: Boston University
- | prexasertib (ACR-368) / Acrivon Therap
Enrollment change, Trial completion date, Trial primary completion date, Metastases: A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency (clinicaltrials.gov) - Jul 5, 2018
P2, N=50, Recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting N=38 --> 50 | Trial completion date: Sep 2021 --> Apr 2022 | Trial primary completion date: Sep 2019 --> Apr 2020
- || bevantolol (SOM3355) / SOM Biotech
New P2a trial: Efficacy and Safety of SOM3355 in Huntington's Disease Chorea (clinicaltrials.gov) - Jul 1, 2018
P2a, N=30, Not yet recruiting, Sponsor: SOM Biotech SL
- |||| prexasertib (ACR-368) / Acrivon Therap
Enrollment open, BRCA Biomarker, PARP Biomarker: A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer (clinicaltrials.gov) - Apr 23, 2018
P2, N=180, Recruiting, Sponsor: Eli Lilly and Company
N=38 --> 50 | Trial completion date: Sep 2021 --> Apr 2022 | Trial primary completion date: Sep 2019 --> Apr 2020 Not yet recruiting --> Recruiting
- ||||||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Trial completion, Trial completion date, Trial primary completion date: IGNITE4: Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections (clinicaltrials.gov) - Apr 11, 2018
P3, N=500, Completed, Sponsor: Tetraphase Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jul 2017 | Trial primary completion date: Dec 2017 --> May 2017
- ||||||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Trial completion, Trial completion date, Trial primary completion date: IGNITE3: Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections (clinicaltrials.gov) - Apr 11, 2018
P3, N=1200, Completed, Sponsor: Tetraphase Pharmaceuticals, Inc.
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jul 2017 | Trial primary completion date: Dec 2017 --> May 2017 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018 | Trial primary completion date: Dec 2018 --> Dec 2017
- | prexasertib (ACR-368) / Acrivon Therap
Trial completion date, Trial primary completion date, BRCA Biomarker, Metastases: A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Apr 5, 2018
P2, N=153, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018 | Trial primary completion date: Dec 2018 --> Dec 2017 Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2019
- || prexasertib (ACR-368) / Acrivon Therap
Trial completion date: A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer (clinicaltrials.gov) - Apr 3, 2018
P2, N=116, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2019 Trial completion date: Jun 2018 --> Sep 2018
- || prexasertib (ACR-368) / Acrivon Therap
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Mar 30, 2018
P1b, N=205, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Jun 2018 --> Sep 2018 Trial completion date: Apr 2019 --> Feb 2020 | Trial primary completion date: Apr 2019 --> Feb 2020
- prexasertib (ACR-368) / Acrivon Therap
Trial completion date: Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Mar 30, 2018
P1, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Apr 2019 --> Feb 2020 | Trial primary completion date: Apr 2019 --> Feb 2020 Trial completion date: May 2021 --> May 2022
- ||||| prexasertib (ACR-368) / Acrivon Therap
New P2 trial, BRCA Biomarker, PARP Biomarker: A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer (clinicaltrials.gov) - Jan 28, 2018
P2, N=180, Not yet recruiting, Sponsor: Eli Lilly and Company
- | prexasertib (LY2606368) / Eli Lilly, Pfizer, SOM Biotech, Ewha Womans University
Preclinical, Journal: Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer. (Pubmed Central) - Jan 18, 2018
Overall, our data provide evidence that prexasertib and olaparib combination resulted in synergistic cytotoxic effects against BRCA wild type HGSOC cells through reduced Rad51 foci formation and greater induction of apoptosis. This may be a novel therapeutic strategy for HGSOC.
- prexasertib (ACR-368) / Acrivon Therap
New P2 trial, Metastases: A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency (clinicaltrials.gov) - Dec 29, 2017
P2, N=38, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- | prexasertib (ACR-368) / Acrivon Therap
New P2 trial, BRCA Biomarker, Metastases: A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Dec 29, 2017
P2, N=78, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | prexasertib (ACR-368) / Acrivon Therap, Lynparza (olaparib) / Merck (MSD), AstraZeneca
New P1 trial, PARP Biomarker: Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 29, 2017
P1, N=24, Not yet recruiting, Sponsor: Khanh Do
- || prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date: A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer (clinicaltrials.gov) - Oct 13, 2017
P2, N=116, Recruiting, Sponsor: Eli Lilly and Company
This may be a novel therapeutic strategy for HGSOC. Trial primary completion date: Apr 2018 --> Aug 2017
- |||| prexasertib (ACR-368) / Acrivon Therap
Enrollment open: A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer (clinicaltrials.gov) - Oct 5, 2017
P2, N=116, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Apr 2018 --> Aug 2017 Active, not recruiting --> Recruiting
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Biomarker, Journal: CHK1 inhibition in small cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib. (Pubmed Central) - Oct 1, 2017
Proteomic analysis identified CHK1 and MYC as top predictive biomarkers of LY2606368 sensitivity, suggesting that CHK1 inhibition may be especially effective in SCLC with MYC amplification or MYC protein overexpression. Our findings provide a preclinical proof of concept supporting the initiation of a clinical efficacy trial in patients with platinum-sensitive or platinum-resistant relapsed SCLC.
- ||||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Enrollment closed: IGNITE3: Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections (clinicaltrials.gov) - Sep 25, 2017
P3, N=1200, Active, not recruiting, Sponsor: Tetraphase Pharmaceuticals, Inc.
Our findings provide a preclinical proof of concept supporting the initiation of a clinical efficacy trial in patients with platinum-sensitive or platinum-resistant relapsed SCLC. Recruiting --> Active, not recruiting
- ||| prexasertib (ACR-368) / Acrivon Therap, ralimetinib (LY 2228820) / Eli Lilly
Trial completion, Trial primary completion date, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov) - Sep 5, 2017
P1, N=70, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Jul 2018 --> May 2017
- | prexasertib (LY2606368) / Eli Lilly, SOM Biotech, Ewha Womans University
Journal: Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. (Pubmed Central) - Aug 3, 2017
Recruiting --> Completed | Trial primary completion date: Jul 2018 --> May 2017 An LY2606368 dose of 105 mg/m(2) once every 14 days is being evaluated as the recommended phase II dose in dose-expansion cohorts for patients with SCC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Combining Chk1/2 inhibition with cetuximab and radiation enhances in vitro and in vivo cytotoxicity in head and neck squamous cell carcinoma. (Pubmed Central) - Aug 3, 2017
P1b
Taken together, the combination of CHKi with cetuximab plus irradiation displayed significant antitumor effects to HNSCCs both in vitro and in vivo, suggesting this combination therapy may increase clinical benefit. A clinical trial to test this treatment for patients with head and neck cancer is currently ongoing (NCT02555644).
- || prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date: A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer (clinicaltrials.gov) - Jul 13, 2017
P2, N=116, Active, not recruiting, Sponsor: Eli Lilly and Company
A clinical trial to test this treatment for patients with head and neck cancer is currently ongoing (NCT02555644). Trial primary completion date: Dec 2017 --> Apr 2018
- ||||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Enrollment closed: IGNITE4: Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections (clinicaltrials.gov) - May 31, 2017
P3, N=400, Active, not recruiting, Sponsor: Tetraphase Pharmaceuticals, Inc.
Trial primary completion date: Dec 2017 --> Apr 2018 Recruiting --> Active, not recruiting
- | prexasertib (ACR-368) / Acrivon Therap
Trial completion, Metastases: A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers (clinicaltrials.gov) - May 22, 2017
P1, N=12, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- prexasertib (ACR-368) / Acrivon Therap
Enrollment closed, Metastases: A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer (clinicaltrials.gov) - May 19, 2017
P1, N=10, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- prexasertib (ACR-368) / Acrivon Therap, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment open, PARP Biomarker: Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 4, 2017
P1, N=24, Recruiting, Sponsor: Khanh Do
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| prexasertib (ACR-368) / Acrivon Therap
Enrollment closed: A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer (clinicaltrials.gov) - Mar 20, 2017
P2, N=116, Active, not recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Mar 9, 2017
P1b, N=185, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2018 --> Apr 2019
- prexasertib (ACR-368) / Acrivon Therap
Enrollment closed, Metastases: A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers (clinicaltrials.gov) - Mar 9, 2017
P1, N=12, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Apr 2018 --> Apr 2019 Recruiting --> Active, not recruiting
- | prexasertib (ACR-368) / Acrivon Therap
Enrollment open: Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (clinicaltrials.gov) - Feb 27, 2017
P1, N=65, Recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting